Anouk In den Kleef

Associate

Amsterdam + 31.20.305.4247

Anouk In den Kleef houdt zich voornamelijk bezig met juridische, fiscale en regelgevingskwesties met betrekking tot particuliere fondsen, waaronder private equity, buy-outs, vastgoed- en schuldfondsen. Zij adviseert over de oprichting van fondsen, waaronder structurering, marketing, governance, documentatie en registratie, en is betrokken bij onderhandelingen met investeerders en heeft diepgaande ervaring met Know Your Customer (KYC)-wetgeving met betrekking tot het onboardingproces voorafgaand aan de closing van een fonds.

Ze heeft talrijke fund reviews uitgevoerd voor investeerders zoals NN Group N.V., Bluemetric, Van Lanschot Kempen Investment Management en Van Lawick Capital, en heeft diverse cliënten geadviseerd over de oprichting van fondsen, waaronder Gilde Healthcare Partners, Capital A Management, Holland Capital Management, Ice Lake Management, BPD RCF Fundmanagement en Beaureale Investments.

Experience

  • Van Lanschot Kempen Investment Management invests in newly established Bouwinvest Dutch Senior Living Impact FundJones Day advised Van Lanschot Kempen Investment Management N.V. in a seed investment by three of their Dutch pension fund clients (Pensioenfonds PostNL, StiPP and Pensioenfonds TNO) in the newly established Bouwinvest Dutch Senior Living Impact Fund, which is a core open-ended fund managed by Bouwinvest focusing on sustainable senior housing in the Netherlands.
  • Egeria Capital Management establishes Egeria Private Equity Fund VIJones Day advised Egeria Capital Management B.V. on the establishment and fundraising of Egeria Private Equity Fund VI (the "Fund"), including the establishment of a friends and family feeder vehicle and the structuring and acquisition of a warehoused investment.
  • DM Capital B.V. forms Dutch Mezzanine Fund IVJones Day is advising DM Capital B.V. on the structuring and fundraising of Dutch Mezzanine Fund IV, a debt fund primarily investing in mezzanine and other private subordinated debt and uni-tranche investments.
  • Greystar launches Dutch Essential Housing VentureJones Day advised Greystar in the establishment of its Dutch Essential Housing Venture in partnership with Stichting Pensioenfonds ABP (through its asset manager, APG Asset Management N.V.).
  • Holland Capital completes €225 million fundraising Holland Capital Growth & Buy Out Fund VJones Day advised Holland Capital on its €225 million fundraising fifth growth and buyout fund, Holland Capital Growth & Buy Out Fund V.
  • Beaureale advised on post-establishment fundraising on cross border basis of Dutch fund structureJones Day advised Beaureale on the post-establishment fundraising in the Netherlands, Germany, France, and Belgium of a Dutch fund structure, to be managed on a cross border basis by Beaureale Group's French AIFM.
  • Climate Fund Managers forms Climate Investor ThreeJones Day advised Climate Fund Managers on the formation of Climate Investor Three, a funding platform for the purpose of investing in energy transition infrastructure companies in the green hydrogen value chain.
  • Gilde Healthcare VI raises €740 millionJones Day represented Gilde Healthcare in connection with the establishment of Gilde Healthcare Venture & Growth VI with €740 million in commitments.
  • IceLake Capital Management B.V. closes IceLake Capital Fund IIJones Day advised IceLake Capital Management B.V. on the fundraising of its second private equity fund, IceLake Capital Fund II, an investment fund for the purpose of investing in small- and medium-sized companies with sustainable competitive advantages and solid growth prospects, with a general focus on the business services and software sectors in the Benelux, closing at €315 million.
  • Capital A completes fundraising of Capital A Fund IVJones Day advised Capital A Management, a specialized mid-market private equity investor, in relation to the fundraising of its Benelux focused private equity fund, Capital A Fund IV.
  • Van Lanschot Kempen Investment Management reviews potential investment in IFM Net Zero Infrastructure FundJones Day assisted Van Lanschot Kempen Investment Management N.V. with a legal and tax fund review in relation to its investment by one or more of its clients in IFM Net Zero Infrastructure Fund.
  • Gilde Healthcare establishes Gilde Healthcare Private Equity IVJones Day advised Gilde Healthcare Partners B.V. in the establishment of Gilde Healthcare Private Equity IV, a private equity fund that invests in profitable healthcare companies operating in the lower mid-market in North-west Europe.
  • Cygnum Capital extends AIFMD licenseJones Day advised Cygnum Capital on the extension of Cygnum Capital's AIFMD license in order to manage public debt funds/feeder AIFs in private and/or public debt.
  • Climate Fund Managers announces first close of CI2, its second global climate fund, at $675 millionJones Day represented Climate Fund Managers (CFM) with the structuring, establishment, fund raising and first closing of the new fund, CI2 Construction Equity Fund, that invests in water, sanitation and oceans infrastructure projects in Africa, South and South East Asia, and Latin America.
  • Greystar announces €725 million close for flagship pan-European closed-end value-add residential strategyJones Day advised Greystar Europe Investment Management B.V., a subsidiary of Greystar Real Estate Partners, LLC, on the closing of €725 million in equity commitments into its flagship pan-European value-add discretionary vehicle.
  • DM Capital completes fundraising of Dutch Mezzanine Fund IIIJones Day advised DM Capital B.V. on the structuring and fundraising of Dutch Mezzanine Fund III, a debt fund primarily investing in mezzanine and other private subordinated debt and uni-tranche investments.
  • Gilde Healthcare V raises €416 million for its venture and growth capital fundJones Day represented Gilde Healthcare in connection with the establishment of Gilde Healthcare V, a venture & growth capital fund that invests in digital and home health, medtech, diagnostics, research tools and instruments, and therapeutics.